ArticleResearch and practice in thrombosis and haemostasis2020
Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.
Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 87 citations in OpenAlex.
- Trial
- Two cases of durvalumab-induced Evans syndrome in biliary tract cancer.Clinical journal of gastroenterology · 2026Article
- Diagnostic and therapeutic challenges in rare hematologic entities: monoclonal gammopathy of thrombotic and bleeding significance.Haematologica · 2026Review
- Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis.Haematologica · 2026Article
- High thrombotic burden in severe Chinese wAIHA patients: a single-center retrospective study.Thrombosis journal · 2026Article
- Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.Journal of the American Heart Association · 2026Observational
- The impact of chemoimmunotherapy on primary cold agglutinin disease and Waldenström macroglobulinemia-associated cold agglutinin syndrome.Frontiers in medicine · 2026Article
- Diagnosis and management of cold agglutinin disease.Hematology. American Society of Hematology. Education Program · 2025Review
- Article
- Cerebral venous sinus thrombosis with cold agglutinin disease in summer: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- [Cold agglutinin disease (CAD)].Innere Medizin (Heidelberg, Germany) · 2025Review
- Bone marrow microenvironment in autoimmune hemolytic anemia: from trephine biopsy to single cell RNA sequencing.Signal transduction and targeted therapy · 2025Article
- Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study.EJHaem · 2025Article
- Cryoproteins in Non-HCV-Related Autoimmune Disorders: A Serious Cold-Induced Problem.Diagnostics (Basel, Switzerland) · 2025Review
- Incidental Cold Agglutinins in Lung Transplant Recipients.Transplantation direct · 2025Article
- The Role of Cold Agglutinins Screening in Cardiac Surgery: Necessity or Redundancy?Sisli Etfal Hastanesi tip bulteni · 2025Article
- Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions.Frontiers in immunology · 2025Review
- Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016-2023.PloS one · 2025Article
- Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024Review
- Sutimlimab for Cold Agglutinin Disease.Journal of the advanced practitioner in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia mediated by IgM autoantibodies that trigger hemolysis via classical complement pathway. Increased incidence of thrombotic events (TEs) has been reported in patients with other forms of hemolysis. The incidence of TEs in patients with CAD is unknown.
objectiveEvaluate TE risk in patients with CAD. PATIENTS/
methodsThis is a matched cohort comparison study evaluating the risk of TEs in patients with CAD and without CAD over a 10-year period. A total of 608 patients with CAD were identified in the Optum Claims-Clinical data set by reviewing clinical notes for CAD terms and matched with up to 10 patients without CAD (N = 5873). TEs were defined as the first medical claim for a TE using International Classification of Diseases, Ninth and Tenth Revision codes. Cox regression models were used to estimate time to first TE. Sensitivity analyses were conducted to estimate TE risk among patients with primary CAD.
resultsAt least 1 TE occurred in 29.6% of patients with CAD and 17.6% of patients without CAD. The proportion of patients experiencing venous, arterial, and cerebral TEs were each higher among CAD patients. The overall risk of having TEs was higher in patients with CAD (adjusted hazard ratio [aHR], 1.94; 95% confidence interval [CI], 1.64-2.30). Patients with presumed primary CAD also demonstrated an increased risk of TEs (aHR, 1.80; 95% CI, 1.46-2.22). Patients with CAD with the fewest comorbidities had 2.44-fold higher risk of having a TE (95% CI, 1.70-3.52).
conclusionsPatients with CAD have an increased risk of TEs when compared with a matched non-CAD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.